

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
SWOG	S1400-SCCA,Adv, Biomarker Master	1	Y 1 Specimen Submission		1425	336	151	71	28	4	07/08/2014	437	218
					1425	336	151	71	28	4			
		2	Y 17 S1400G		37	37	20	7	5	0			
			2 S1400A		160	0	0	0	0	0	07/08/2014		
			21 S1400F		7	7	7	7	4	1			
			3 S1400B		53	1	0	0	0	0			
			4 S1400C		88	0	0	0	0	0			
			5 S1400D		92	0	0	0	0	0			
			6 S1400E		16	0	0	0	0	0			
			7 S1400I		644	252	112	49	11	0			
					1097	297	139	63	20	1			
		3	P 10 S1400I		8	4	2	1	0	0			
			18 S1400G		8	8	4	2	0	0			
			22 S1400F		1	1	1	1	1	1			
			8 S1400B		1	0	0	0	0	0	07/08/2014		
					18	13	7	4	1	1			
	S1400A-Non-Match: MEDI4736	1	N 1 MEDI4736	140	78	0	0	0	0	0	07/31/2014		
			2 Docetaxel		38	0	0	0	0	0			
					116	0	0	0	0	0			
		2	Y 3 MEDI4736	140	4	3	1	1	0	0	07/31/2014		
					4	3	1	1	0	0			
	S1400G-HRRD: Talazoparib (BMN 673)	1	Y 1 Talazoparib (BMN 673)	60	32	32	20	7	2	1	03/03/2017	439	219
					32	32	20	7	2	1			
	S1400I-Non-Match: Nivo + Ipi vs Nivo	1	Y 1 Nivolumab + Ipilimumab	350	122	54	24	14	5	1	12/29/2015	434	217
			2 Nivolumab		123	54	23	13	5	1			
					245	108	47	27	10	2			
	S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab	1	Y 1 AFATINIB + CETUXIMAB	605	77	39	20	10	4	1	05/07/2015	225	95
			2 AFATINIB		73	36	20	8	1	0			
					150	75	40	18	5	1			
	S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	1	Y 1 Trametinib + Docetaxel	53	44	39	18	7	3	1	10/05/2016	208	92

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs		
					TOTAL REGS.	LAST Month	LAST Month	LAST Month	LAST 30 DAYS				LAST 7 DAYS	
					44	39	18	7	3	1				
	8811-NSCLC, Stage III,ChemoRT+ABT-888	1	N 5	RT+Pac+Carbo+blinded drug	132	18	17	8	2	0	01/24/2013	131	53	
			6	RT+Pac+Carbo+blinded drug		14	12	4	2	0	0			
						32	29	12	4	0	0			
		2	Y 8	Pac + Carbo + blinded drug	132	21	21	16	7	2	0	01/24/2013		
						21	21	16	7	2	0			
Yes	A081105-ALCHEMIST1, EGFR mut, Erlotinib	1	E	Total Registrations		29	17	7	4	1	0	04/01/2015	248	
						29	17	7	4	1	0			
	A151216-ALCHEMIST0 - screening	1	E	Total Registrations		401	209	116	58	19	6	12/16/2014	452	251
						401	209	116	58	19	6			
	C30610-SCLC, Thoracic RT	1	E	Total Registrations		54	4	4	2	2	0	05/14/2008	239	118
						54	4	4	2	2	0			
	E4512-ALCHEMIST2, ALK mut, Crizotinib	1	E	Total Registrations		6	3	3	2	0	0	02/29/2016	456	257
						6	3	3	2	0	0			
	NRGCC003-SCLC, PCI or HA-PCI	1	E	Total Registrations		4	3	3	1	0	0	10/20/2016	320	143
						4	3	3	1	0	0			
		2	E	Total Registrations		4	3	3	1	0	0	10/20/2016		
						4	3	3	1	0	0			
	R1306-NSCLC,Adv,ALK/EGFR,TargetAgents	1	E	Total Registrations		8	0	0	0	0	0	03/12/2014	189	79
						8	0	0	0	0	0			
No	A151216-ALCHEMIST0 - screening	0	E	Total Registrations		407	210	113	58	18	6	12/16/2014	452	251
						407	210	113	58	18	6			
	EA5142-ALCHEMIST3, Non-match, Nivolumab	1	E	Total Registrations		26	21	14	9	2	0	08/03/2016	406	230
						26	21	14	9	2	0			

19-NOV-2017 6:10
LUNG Open Studies with No Registrations

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1400F Non-Match: MEDI4736 + Tremelimumab	1 Registration	02-Oct-17
S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	1 Neoadjuvant Therapy	03-Nov-17
	2 Surgery	03-Nov-17
	3 Maintenance	03-Nov-17